David P. King, Chairman and Chief Executive Officer of LabCorp, commented, "This collaboration combines the complementary strengths of two leading central laboratories to support drug development. The transaction is an important milestone as it enhances LabCorp's clinical trials central lab offering to customers in key geographies and advances the Company's companion diagnostics and personalized medicine strategy."
Source: MarketWatch



.gif)
0 comments:
Post a Comment